Table 3 Univariate analysis of prognostic factors for overall survival and progression-free survival of Burkitt lymphoma.
From: Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China
Overall survival | Progression free survival | |||
|---|---|---|---|---|
HR (95% CI) from Cox regression | p-value from log rank test | HR (95% CI) from Cox regression | p-value from log rank test | |
Age > 60 | 25.882 (0.018, 36834.702) | 0.380 | 25.780 (0.008, 82277.338) | 0.430 |
High Risk IPI | 0.039 (0.000, 1099.400) | 0.534 | 0.039 (0.000, 3454.451) | 0.576 |
ECOG PS > 1 | 0.332 (0.046, 2.411) | 0.276 | 0.236 (0.030, 1.849) | 0.169 |
Number of extranodal sites ≥ 2 | 0.119 (0.005, 2.775) | 0.185 | 0.091 (0.003, 2.746) | 0.168 |
Bulky disease | 0.278 (0.018, 4.243) | 0.357 | 0.483 (0.043, 5.391) | 0.554 |
B symptoms | 10.068 (1.923, 52.715) | 0.006 | 8.733 (1.429, 53.348) | 0.019 |
Bone marrow involvement | 0.302 (0.034, 2.700) | 0.284 | 0.163 (0.012, 2.228) | 0.174 |
Elevated LDH | 30.608 (0.020, 46159.610) | 0.360 | 18.037 (0.013, 24985.425) | 0.433 |
CNS Involvement | 10.548 (0.699, 159.127) | 0.089 | 70.715 (1.620, 3087.164) | 0.027 |
CD4 count < 100/µL | 12.485 (2.443, 63.800) | 0.002 | 8.231 (1.916, 35.356) | 0.005 |
Rituximab use | 0.420 (0.040, 4.415) | 0.470 | 0.575 (0.050, 6.550) | 0.655 |
